1. Home
  2. MREO vs FBIZ Comparison

MREO vs FBIZ Comparison

Compare MREO & FBIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • FBIZ
  • Stock Information
  • Founded
  • MREO 2015
  • FBIZ 1909
  • Country
  • MREO United Kingdom
  • FBIZ United States
  • Employees
  • MREO N/A
  • FBIZ N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • FBIZ Major Banks
  • Sector
  • MREO Health Care
  • FBIZ Finance
  • Exchange
  • MREO Nasdaq
  • FBIZ Nasdaq
  • Market Cap
  • MREO 326.1M
  • FBIZ 390.3M
  • IPO Year
  • MREO N/A
  • FBIZ N/A
  • Fundamental
  • Price
  • MREO $1.97
  • FBIZ $50.26
  • Analyst Decision
  • MREO Strong Buy
  • FBIZ Buy
  • Analyst Count
  • MREO 5
  • FBIZ 3
  • Target Price
  • MREO $7.40
  • FBIZ $58.67
  • AVG Volume (30 Days)
  • MREO 1.3M
  • FBIZ 39.5K
  • Earning Date
  • MREO 11-11-2025
  • FBIZ 10-30-2025
  • Dividend Yield
  • MREO N/A
  • FBIZ 2.27%
  • EPS Growth
  • MREO N/A
  • FBIZ 22.50
  • EPS
  • MREO N/A
  • FBIZ 5.60
  • Revenue
  • MREO $500,000.00
  • FBIZ $150,952,000.00
  • Revenue This Year
  • MREO N/A
  • FBIZ $17.98
  • Revenue Next Year
  • MREO $72.16
  • FBIZ $8.16
  • P/E Ratio
  • MREO N/A
  • FBIZ $9.11
  • Revenue Growth
  • MREO N/A
  • FBIZ 8.24
  • 52 Week Low
  • MREO $1.47
  • FBIZ $41.50
  • 52 Week High
  • MREO $4.72
  • FBIZ $56.46
  • Technical
  • Relative Strength Index (RSI)
  • MREO 57.79
  • FBIZ 46.54
  • Support Level
  • MREO $1.94
  • FBIZ $49.23
  • Resistance Level
  • MREO $2.12
  • FBIZ $51.92
  • Average True Range (ATR)
  • MREO 0.11
  • FBIZ 0.98
  • MACD
  • MREO 0.02
  • FBIZ -0.21
  • Stochastic Oscillator
  • MREO 62.65
  • FBIZ 33.05

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About FBIZ First Business Financial Services Inc.

First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically all the business activity functioned through the region of the United States.

Share on Social Networks: